Journal
ANNALS OF ONCOLOGY
Volume 28, Issue 4, Pages 702-710Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdx010
Keywords
ovarian cancer; consensus conference; GCIG; individualized therapy; recommendations
Categories
Funding
- Astra Zeneca UK Limited (UK)
- Bristol-Myers Squibb Company (USA)
- Clovis Oncology Inc. (USA)
- Eisai Co., Ltd. (Japan)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer Inc. (USA)
- Pharma Mar, S.A. (Spain)
- TESARO, Inc. (USA)
- Zeria Pharmaceutical Co., Ltd. (Japan)
- MRC [G0501974] Funding Source: UKRI
- Medical Research Council [G0501974] Funding Source: researchfish
- Ovarian Cancer Action [OCA6] Funding Source: researchfish
Ask authors/readers for more resources
This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the consensus process, which is intended to guide future research initiatives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available